• Mutation; HGNC; HGNC:11998; TP53; Simple; p.Arg209Ter (c.625A>T); Zygosity=Unspecified (PubMed=10841287).
  

PubMed=9809028; DOI=10.1016/S0165-4608(98)00076-4
Gasperi-Campani A., Roncuzzi L., Ricotti L., Lenzi L., Gruppioni R., Sensi A., Zini N., Zoli W., Amadori D.
Molecular and biological features of two new human squamous and adenocarcinoma of the lung cell lines.
Cancer Genet. Cytogenet. 107:11-20(1998)

PubMed=10574245; DOI=10.1038/sj.bjc.6690737; PMCID=PMC2362882
Zoli W., Ricotti L., Dal Susino M., Barzanti F., Frassineti G.L., Folli S., Tesei A., Bacci F., Amadori D.
Docetaxel and gemcitabine activity in NSCLC cell lines and in primary cultures from human lung cancer.
Br. J. Cancer 81:609-615(1999)

PubMed=10841287
Calistri D., Barzanti F., Dal Susino M., Fedriga R., Saragoni L., Bernardi L., Ricotti L., Zoli W.
Correlation between p53 gene mutations and p53 protein accumulation evaluated by different methodologies.
J. Biol. Regul. Homeost. Agents 14:120-127(2000)

PubMed=26919099; DOI=10.18632/oncotarget.7575; PMCID=PMC4951299
Arienti C., Zanoni M., Pignatta S., Del Rio A., Carloni S., Tebaldi M., Tedaldi G., Tesei A.
Preclinical evidence of multiple mechanisms underlying trastuzumab resistance in gastric cancer.
Oncotarget 7:18424-18439(2016)